Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
In a survey of the spectrum of mutational burdens in 27 types of cancers, there was a correlation between an increased mutational burden and the response to checkpoint inhibition of PD-1 and PD-L1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, these studies are limited to particular cancer types and subsets of patients, due to difference in mutation load seen in different cancer types, and immune-related adverse effects of therapy may occur [93][94][95][96].”
From Cancer-on-chip models for metastasis: importance of the tumor microenvironment (2024) · cites this paper as [93]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While these markers have clinical utility in specific contexts, their predictive accuracy varies considerably across tumor histologies and patient populations.”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While high TMB and immune checkpoint molecule expression, including PD-L1, have been used as predictive biomarkers across different cancer types, they have limited clinical utility when considered in isolation88,101.”
From Multi-omic analysis of hepatocellular carcinoma reveals aberrant cis-regulatory changes and dysregulated retrotransposons with prognostic potential (2025) · cites this paper as [88]
Experimental — accuracy not yet measuredIn the citing paper
“Although high TMB led to FDA approval, it should be noted that certain tumor types with moderate TMB carry relatively high response rates to ICT, such as clear cell RCC (128, 129).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [128]
In the citing paper
“Melanoma, lung, and bladder cancer, tumors commonly associated with an increased number of mutations due to environmental DNA damage, exhibit a stronger response to ICB (Yarchoan et al., 2017).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Yarchoan et al., 2017
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519
PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma
Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603702 · Cited by 1,258
Cited by
Items 101–200 of 1,006
Huber, V., Vallacchi, V., Fleming, V., Hu, X., Cova, A., Dugo, M., Shahaj, E., Sulsenti, R., Vergani, E., Filipazzi, P., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci98060 · Cited by 250
Oliva, M., Spreafico, A., Taberna, M., Alemany, L., Coburn, B., Mesia, R., & Siu, L. L. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy507 · Cited by 260
“An initial retrospective analysis of 27 tumor types and subtypes among patients who received PD-1/PD-L1 inhibitors demonstrated a significant correlation between TMB and response rate to these agents [77].”
BackgroundRizzo, A., Ricci, A. D., & Brandi, G. (2021) · Cancers · doi:10.3390/cancers13030558 · Cited by 259
“TMB is commonly defined as the overall number of somatic nonsynonymous mutations per megabase (Mut/Mb), including frame-shift mutations, insertions, point mutations, and deletions [44,45].”
BackgroundTargeted therapy for hepatocellular carcinoma: Challenges and opportunities
Chen, S., Cao, Q., Wen, W., & Wang, H. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.114428 · Cited by 255
Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control
Lhuillier, C., Rudqvist, N.-P., Yamazaki, T., Zhang, T., Charpentier, M., Galluzzi, L., Dephoure, N., Clement, C. C., Santambrogio, L., Zhou, X. K., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci138740 · Cited by 240
“1172/JCI138740 8 els of an antigenic mutation, and not only its presence in the genome, are critical (32, 33).”
BackgroundT-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments
Daver, N., Alotaibi, A. S., Bücklein, V., & Subklewe, M. (2021) · Leukemia · doi:10.1038/s41375-021-01253-x · Cited by 249
Paver, E. C., Cooper, W. A., Colebatch, A. J., Ferguson, P. M., Hill, S. K., Lum, T., Shin, J.-S., O'Toole, S., Anderson, L., Scolyer, R. A., et al. (2021) · Pathology · doi:10.1016/j.pathol.2020.10.007 · Cited by 242
Kim, C. G., Jang, M., Kim, Y., Leem, G., Kim, K. H., Lee, H., Kim, T.-S., Choi, S. J., Kim, H.-D., Han, J. W., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aay0555 · Cited by 245
“Although MSS CRC has lower levels of tumor mutation burden than MSI CRC, tumor mutation burden alone cannot explain the lack of response to anti–PD-1 therapy in MSS CRC (26, 27).”
BackgroundStenzinger, A., Allen, J. D., Maas, J., Stewart, M. D., Merino, D. M., Wempe, M. M., & Dietel, M. (2019) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.22733 · Cited by 239
Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
Peyraud, F., & Italiano, A. (2020) · Cancers · doi:10.3390/cancers12061502 · Cited by 242
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma
Rosellini, M., Marchetti, A., Mollica, V., Rizzo, A., Santoni, M., & Massari, F. (2023) · Nature Reviews Urology · doi:10.1038/s41585-022-00676-0 · Cited by 240
Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts
Fumet, J.-D., Truntzer, C., Yarchoan, M., & Ghiringhelli, F. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.02.038 · Cited by 237
Self-citationDevelopment of PARP and immune-checkpoint inhibitor combinations
Stewart, R. A., Pilié, P. G., & Yap, T. A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-2652 · Cited by 239
Lee, J. S., & Ruppin, E. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.2311 · Cited by 228
“Thirty-six variables of 3 distinct classes considered were associated with (1) tumor neoantigens, (2) tumor microenvironment and inflammation, and (3) the checkpoint targets.”
BackgroundLearning from clinical trials of neoadjuvant checkpoint blockade
Versluis, J. M., Long, G. V., & Blank, C. U. (2020) · Nature Medicine · doi:10.1038/s41591-020-0829-0 · Cited by 234
Clinical cancer genomic profiling
Chakravarty, D., & Solit, D. B. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00338-8 · Cited by 226
Zeh, H. J., Bahary, N., Boone, B. A., Singhi, A. D., Miller-Ocuin, J. L., Normolle, D. P., Zureikat, A. H., Hogg, M. E., Bartlett, D. L., Lee, K. K., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4042 · Cited by 233
“The lack of response to modern immune therapies in pancreatic cancer remains incompletely understood, but may be related to a combination of T-cell exclusion and the low number of synonymous mutations found in pancreatic cancer, with which a diminished response to checkpoint therapies has been associated (27).”
BackgroundZhang, X., Shi, M., Chen, T., & Zhang, B. (2020) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2020.08.030 · Cited by 232
“However, less than 20% of HNSC patients responded to immunotherapy as compared with patients with other tumor types with lower immune infiltration.(3,36) This insinuates that even the immune phenotypes in the tumor cannot absolutely predict the response to immunotherapy.”
ResultCurrent advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma
Fan, J.-Q., Wang, M.-F., Chen, H.-L., Shang, D., Das, J. K., & Song, J. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01151-3 · Cited by 230
ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis
Liu, H., Kuang, X., Zhang, Y., Ye, Y., Li, J., Liang, L., Xie, Z., Weng, L., Guo, J., Li, H., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.02.006 · Cited by 227
Biomarkers for immunotherapy of hepatocellular carcinoma
Greten, T. F., Villanueva, A., Korangy, F., Ruf, B., Yarchoan, M., Ma, L., Ruppin, E., & Wang, X. W. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00816-4 · Cited by 227
“TMB is a potential pan-tumour biomarker of benefit from anti-PD-1 antibodies 42 , although no clear relationship between TMB and either response rate or OS was detected in a subset of 130 patients enrolled in the IMbrave150 trial 37 .”
BackgroundSelf-citationIntrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity
Mahadevan, N. R., Knelson, E. H., Wolff, J. O., Vajdi, A., Saigí, M., Campisi, M., Hong, D., Thai, T. C., Piel, B., Han, S., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0913 · Cited by 227
“The addition of immune checkpoint blockade (ICB) to first-line chemotherapy has yielded relatively modest benefit and durable responses are rare, despite SCLC’s high tumor mutation burden (4,5).”
BackgroundHarnessing the immune system in glioblastoma
Brown, N. F., Carter, T. J., Ottaviani, D., & Mulholland, P. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0258-8 · Cited by 223
Francescone, R., Barbosa Vendramini-Costa, D., Franco-Barraza, J., Wagner, J., Muir, A., Lau, A. N., Gabitova, L., Pazina, T., Gupta, S., Luong, T., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0775 · Cited by 222
Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer
Bowling, E. A., Wang, J. H., Gong, F., Wu, W., Neill, N. J., Kim, I. S., Tyagi, S., Orellana, M., Kurley, S. J., Dominguez-Vidaña, R., et al. (2021) · Cell · doi:10.1016/j.cell.2020.12.031 · Cited by 224
“, 2016) and these features strongly associate with success of immune-checkpoint blockade (Cristescu et al., 2018; Goodman et al., 2017; Hugo et al., 2016; Rizvi et al., 2015; Yarchoan et al., 2017).”
BackgroundPD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging—A Literature Review
Planes-Laine, G., Rochigneux, P., Bertucci, F., Chrétien, A.-S., Viens, P., Sabatier, R., & Gonçalves, A. (2019) · Cancers · doi:10.3390/cancers11071033 · Cited by 221
“Indeed, Yarchoan et al. described a significant correlation between the tumor mutational burden and the objective response rate to PD-1 inhibition ( p < 0.001) [24].”
BackgroundInfluentialWang, Y., Tong, Z., Zhang, W., Zhang, W., Buzdin, A., Mu, X., Yan, Q., Zhao, X., Chang, H.-H., Duhon, M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.683419 · Cited by 224
“For example, Merkel cell carcinoma (MCC), renal cell cancers (RCC), and mesothelioma all have higher response rates to ICIs than would be anticipated from their TMBs (58) due to the higher quality of antigens in these tumor types.”
BackgroundCurrent status of immune checkpoint inhibitors for gastric cancer
Kono, K., Nakajima, S., & Mimura, K. (2020) · Gastric Cancer · doi:10.1007/s10120-020-01090-4 · Cited by 220
Cancer immunotherapy: it’s time to better predict patients’ response
Pilard, C., Ancion, M., Delvenne, P., Jerusalem, G., Hubert, P., & Herfs, M. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01413-x · Cited by 205
Advancing to the era of cancer immunotherapy
Wang, Y., Wang, M., Wu, H., & Xu, R. (2021) · Cancer Communications · doi:10.1002/cac2.12178 · Cited by 214
New clinical trial design in precision medicine: discovery, development and direction
Duan, X.-P., Qin, B.-D., Jiao, X.-D., Liu, K., Wang, Z., & Zang, Y.-S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01760-0 · Cited by 197
Keenan, B. P., Fong, L., & Kelley, R. K. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0749-z · Cited by 220
Immune Checkpoint Inhibitor Therapy in Oncology
Tan, S., Day, D., Nicholls, S. J., & Segelov, E. (2022) · JACC: CardioOncology · doi:10.1016/j.jaccao.2022.09.004 · Cited by 205
“TMB, defined as the total number of mutations per coding area of tumor DNA,(75) is predictive of response to CTLA-4 inhibitors(76-78) and PD-1/PD-L1 inhibitors.(75) It has been hypothesized that increased TMB leads to increased expression of different tumor neoantigens (peptides unique to cancer cells), thus enhanced…”
BackgroundMulti-omics prediction of immune-related adverse events during checkpoint immunotherapy
Jing, Y., Liu, J., Ye, Y., Pan, L., Deng, H., Wang, Y., Yang, Y., Diao, L., Lin, S. H., Mills, G. B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18742-9 · Cited by 215
van Dessel, L. F., van Riet, J., Smits, M., Zhu, Y., Hamberg, P., van der Heijden, M. S., Bergman, A. M., van Oort, I. M., de Wit, R., Voest, E. E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13084-7 · Cited by 207
Zemek, R. M., De Jong, E., Chin, W. L., Schuster, I. S., Fear, V. S., Casey, T. H., Forbes, C., Dart, S. J., Leslie, C., Zaitouny, A., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav7816 · Cited by 212
“Although several correlates of response to ICB have been reported, such as expression of checkpoint ligands (8), mutational load (9), neoantigen expression (10), interferon (IFN) signatures (11), and an inflammatory tumor microenvironment (12), no definitive predictive biomarkers have been identified (6).”
BackgroundAllgäuer, M., Budczies, J., Christopoulos, P., Endris, V., Lier, A., Rempel, E., Volckmar, A.-L., Kirchner, M., von Winterfeld, M., Leichsenring, J., et al. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.08.14 · Cited by 212
Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
Zhao, B., Zhao, H., & Zhao, J. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920937612 · Cited by 207
Emerging strategies for combination checkpoint modulators in cancer immunotherapy
Popovic, A., Jaffee, E. M., & Zaidi, N. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120775 · Cited by 212
Self-citationZhang, S., Zhang, Y., Feng, Y., Wu, J., Hu, Y., Lin, L., Xu, C., Chen, J., Tang, Z., Tian, H., et al. (2022) · Advanced Materials · doi:10.1002/adma.202206851 · Cited by 208
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
Thomas, R., Al-Khadairi, G., & Decock, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.600573 · Cited by 202
“Furthermore, tumor mutational burden has been correlated with higher objective response rates to anti-PD1 or anti-PD-L1 monotherapy across 27 solid tumor types (29).”
BackgroundFang, W., Ma, Y., Yin, J. C., Hong, S., Zhou, H., Wang, A., Wang, F., Bao, H., Wu, X., Yang, Y., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0585 · Cited by 207
“org Clin Cancer Res; 25(16) August 15, 2019 5019”
BackgroundInfluentialThe evolving landscape of biomarker testing for non-small cell lung cancer in Europe
Kerr, K. M., Bibeau, F., Thunnissen, E., Botling, J., Ryška, A., Wolf, J., Öhrling, K., Burdon, P., Malapelle, U., & Büttner, R. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.02.026 · Cited by 202
Immune-based therapies for hepatocellular carcinoma
Pinato, D. J., Guerra, N., Fessas, P., Murphy, R., Mineo, T., Mauri, F. A., Mukherjee, S. K., Thursz, M., Wong, C. N., Sharma, R., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1249-9 · Cited by 202
Zhang, Y., Ma, S., Liu, X., Xu, Y., Zhao, J., Si, X., Li, H., Huang, Z., Wang, Z., Tang, Z., et al. (2021) · Advanced Materials · doi:10.1002/adma.202007293 · Cited by 199
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
Arora, S., Velichinskii, R., Lesh, R. W., Ali, U., Kubiak, M., Bansal, P., Borghaei, H., Edelman, M. J., & Boumber, Y. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01051-z · Cited by 196
Magré, L., Verstegen, M. M. A., Buschow, S., van der Laan, L. J. W., Peppelenbosch, M., & Desai, J. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006290 · Cited by 178
“8 Such characteristics often lead to significant influx of immune cells at the tumor site due to neoantigen release.”
BackgroundChen, X., Pan, X., Zhang, W., Guo, H., Cheng, S., He, Q., Yang, B., & Ding, L. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.09.006 · Cited by 197
Rationale and Design of the Targeted Agent and Profiling Utilization Registry Study
Mangat, P. K., Halabi, S., Bruinooge, S. S., Garrett-Mayer, E., Alva, A., Janeway, K. A., Stella, P. J., Voest, E., Yost, K. J., Perlmutter, J., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00122 · Cited by 189
Tímár, J., & Ladányi, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105384 · Cited by 164
Anagnostou, V., Niknafs, N., Marrone, K., Bruhm, D. C., White, J. R., Naidoo, J., Hummelink, K., Monkhorst, K., Lalezari, F., Lanis, M., et al. (2020) · Nature Cancer · doi:10.1038/s43018-019-0008-8 · Cited by 200
Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials
Egen, J. G., Ouyang, W., & Wu, L. C. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.010 · Cited by 197
Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer
Prelaj, A., Tay, R., Ferrara, R., Chaput, N., Besse, B., & Califano, R. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.002 · Cited by 193
Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy
Wu, H.-L., Gong, Y., Ji, P., Xie, Y.-F., Jiang, Y.-Z., & Liu, G.-Y. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01263-x · Cited by 186
“Imbalance of nucleotide pools between purines and pyrimidines could generate PTMB and subsequently increase neoantigens and immunogenicity as mentioned above [186, 187, 249].”
BackgroundBiomarkers of response to PD-1 pathway blockade
Li, H., van der Merwe, P. A., & Sivakumar, S. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01743-4 · Cited by 183
“associated with Merkel cell polyomavirus and human papilloma virus, respectively, respond better to PD-1 pathway blockade than would be predicted by TMB alone [6].”
BackgroundResultInfluentialBeta2-microglobulin(B2M) in cancer immunotherapies: Biological function, resistance and remedy
Wang, H., Liu, B., & Wei, J. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.06.008 · Cited by 190
Wang, Y.-S., Kumari, M., Chen, G.-H., Hong, M.-H., Yuan, J. P.-Y., Tsai, J.-L., & Wu, H.-C. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00977-5 · Cited by 173
“PDAC patients are largely insensitive to immune checkpoint inhibitors and exhibit high recurrence rates with a 5-year survival of only 8–10% after surgery [179, 261].”
BackgroundDeep Insight of Design, Mechanism, and Cancer Theranostic Strategy of Nanozymes
Yang, L., Dong, S., Gai, S., Yang, D., Ding, H., Feng, L., Yang, G., Rehman, Z., & Yang, P. (2024) · Nano-Micro Letters · doi:10.1007/s40820-023-01224-0 · Cited by 182
Duraiswamy, J., Turrini, R., Minasyan, A., Barras, D., Crespo, I., Grimm, A. J., Casado, J., Genolet, R., Benedetti, F., Wicky, A., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.10.008 · Cited by 190
Bando, H., Tsukada, Y., Inamori, K., Togashi, Y., Koyama, S., Kotani, D., Fukuoka, S., Yuki, S., Komatsu, Y., Homma, S., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3213 · Cited by 170
“Because TMB is associated with a high frequency of neoantigens (41), those patients might be expected to have a higher efficacy similar to that observed in MSI-H LARC.”
ResultNext-Generation CAR T-cell Therapies
Young, R. M., Engel, N. W., Uslu, U., Wellhausen, N., & June, C. H. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1683 · Cited by 179
Weinberg, B. A., Xiu, J., Lindberg, M. R., Shields, A. F., Hwang, J. J., Poorman, K., Salem, M. E., Pishvaian, M. J., Holcombe, R. F., Marshall, J. L., et al. (2019) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.08.18 · Cited by 185
“Abundant somatic mutations in solid tumors have been associated with a greater responsiveness to immune checkpoint inhibitors (20,21,49).”
BackgroundBioengineered nanogels for cancer immunotherapy
Ma, X., Li, S.-J., Liu, Y., Zhang, T., Xue, P., Kang, Y., Sun, Z.-J., & Xu, Z. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00247g · Cited by 185
Salem, M. E., Puccini, A., Xiu, J., Raghavan, D., Lenz, H.-J., Korn, W. M., Shields, A. F., Philip, P. A., Marshall, J. L., & Goldberg, R. M. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0143 · Cited by 185
“TMB-high has been associated with improved sensitivity to immune checkpoint inhibitors [32, 33]; therefore, it may be a useful biomarker, together with PD-L1 and MSI-H/dMMR status, to better select those patients who will benefit from immunotherapy.”
BackgroundKabacaoglu, D., Ciecielski, K. J., Ruess, D. A., & Algül, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01878 · Cited by 179
Biomarkers for Hepatobiliary Cancers
Nault, J., & Villanueva, A. (2021) · Hepatology · doi:10.1002/hep.31175 · Cited by 178
“Proposed biomarkers of response to CPI include PD1 ligand (PDL1) expression, tumor mutational burden,(42) aneuploidy,(43) and gene signatures.”
BackgroundPredicting tumour radiosensitivity to deliver precision radiotherapy
Price, J. M., Prabhakaran, A., & West, C. M. L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00709-y · Cited by 167
Tumour mutational burden: clinical utility, challenges and emerging improvements
Budczies, J., Kazdal, D. N., Menzel, M., Beck, S., Kluck, K., Altbürger, C., Schwab, C., Allgäuer, M., Ahadova, A., Kloor, M., et al. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00932-9 · Cited by 218
Eso, Y., Shimizu, T., Takeda, H., Takai, A., & Marusawa, H. (2020) · Journal of Gastroenterology · doi:10.1007/s00535-019-01620-7 · Cited by 174
He, J., Xiong, X., Yang, H., Li, D., Liu, X., Li, S., Liao, S., Chen, S., Wen, X., Yu, K., et al. (2022) · Cell Research · doi:10.1038/s41422-022-00627-9 · Cited by 178
“Objective response rate of each cancer type was collected as reported.(28) The relationship between the median CXCL13 expression and objective response rate was analyzed with the methods of Spearman.”
MethodTumor mutation burden: from comprehensive mutational screening to the clinic
Galuppini, F., Dal Pozzo, C. A., Deckert, J., Loupakis, F., Fassan, M., & Baffa, R. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0929-4 · Cited by 168
Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy
Wang, S., Cowley, L. A., & Liu, X.-S. (2019) · Molecules · doi:10.3390/molecules24183214 · Cited by 180
“Most tumor types show response rates below 40% to PD-1 inhibition; the objective response rates of each tumor type are reported to be highly correlated with the tumor mutational burden (TMB) of each tumor type [44].”
BackgroundImmunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions
Mao, L., Qi, Z., Zhang, L., Guo, J., & Si, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.680407 · Cited by 172
“Given the role of the TMB and tumor immune micro environment in clinical responses to immunotherapy and targeted therapies, the molecular differences between melanomas in Asian and Caucasian patients may be critical drivers of any disparities in treatment response between these populations.”
BackgroundInfluentialWhite paper on microbial anti-cancer therapy and prevention
Forbes, N. S., Coffin, R. S., Deng, L., Evgin, L., Fiering, S., Giacalone, M., Gravekamp, C., Gulley, J. L., Gunn, H., Hoffman, R. M., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0381-3 · Cited by 168
Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes
Kim, S. I., Cassella, C. R., & Byrne, K. T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.629722 · Cited by 168
Knepper, T. C., Montesion, M., Russell, J. S., Sokol, E. S., Frampton, G. M., Miller, V. A., Albacker, L. A., McLeod, H. L., Eroglu, Z., Khushalani, N. I., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4159 · Cited by 168
“However, in MCC frequent response to immune checkpoint therapy inMCPyV-positive cases has contributed to a response rate that exceeds what would be predicted by median TMB alone (53).”
BackgroundCristescu, R., Aurora-Garg, D., Albright, A., Xu, L., Liu, X. Q., Loboda, A., Lang, L., Jin, F., Rubin, E. H., Snyder, A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003091 · Cited by 164
Azad, N. S., Gray, R. J., Overman, M. J., Schoenfeld, J. D., Mitchell, E. P., Zwiebel, J. A., Sharon, E., Streicher, H., Li, S., McShane, L. M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00818 · Cited by 169
“This inability to repair primarily single base pair mismatches in DNA results in the accumulation of DNA mutations and provides MMR-deficient cancers with one of the highest tumor mutation burdens (TMBs) among cancers, which has been correlated with clinical response to anti–PD-1/PD-L1 therapy.(3,4)”
BackgroundStrategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma
Xing, R., Gao, J., Cui, Q., & Wang, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.783236 · Cited by 167
“In addition, a study revealed a significant correlation between tumor mutation burden (TMB) and clinical outcomes after PD-1 inhibitors (99).”
Serratì, S., Guida, M., Di Fonte, R., De Summa, S., Strippoli, S., Iacobazzi, R. M., Quarta, A., De Risi, I., Guida, G., Paradiso, A., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01490-9 · Cited by 159
“Despite both are predictors of a better response to ICI, they are not fully satisfactory because such evaluations are not effective in capturing the dynamic spatial and temporal heterogeneity of the tumor [5] and additionally they return indistinct antigenic value of individual mutations [6].”
Fang, Y., Liu, W., Tang, Z., Ji, X., Zhou, Y., Song, S., Tian, M., Tao, C., Huang, R., Zhu, G., et al. (2023) · Hepatology · doi:10.1002/hep.32348 · Cited by 162
“[2,3] However, patient resistance to immunotherapy is observed in more than 60% of reported cases across multiple cancer types; such resistance can be caused by diverse factors, including aberrant metabolic properties of tumor cells.[4,5] Tumor cells are able to construct an immune suppressive microenvironment by comp…”
BackgroundKinkead, H. L., Hopkins, A., Lutz, E., Wu, A. A., Yarchoan, M., Cruz, K., Woolman, S., Vithayathil, T., Glickman, L. H., Ndubaku, C. O., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122857 · Cited by 166
Self-citationPan-cancer association of HLA gene expression with cancer prognosis and immunotherapy efficacy
Schaafsma, E., Fugle, C. M., Wang, X., & Cheng, C. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01400-2 · Cited by 167
“5d).(41) We indeed observed a positive relationship between response and HLA gene expression (SCC= 0.”
Metastatic uveal melanoma: The final frontier
Rantala, E., Hernberg, M., Piperno‐Neumann, S., Grossniklaus, H. E., & Kivelä, T. T. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101041 · Cited by 180
Choucair, K., Morand, S., Stanbery, L., Edelman, G., Dworkin, L., & Nemunaitis, J. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-0174-y · Cited by 164
“study which assessed the correlation between diverse antiPD1 or anti-PD-L1 therapies, the cohort included patients with: adrenocortical cancer (n= 2), anal cancer (n= 3), germ cell tumor (n= 16), gliobastoma multiform (GBM; n = 35), mesothelioma (n= 57), pancreatic cancer (n= 36), prostate cancer (n= 77), and sarcoma…”
BackgroundInfluentialAng, C., Klempner, S. J., Ali, S. M., Madison, R., Ross, J. S., Severson, E. A., Fabrizio, D., Goodman, A., Kurzrock, R., Suh, J., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.26998 · Cited by 163
“While increasing TMB correlates with higher response rates to PD-1 inhibitors [14–17], only 55% of the differences observed across tumor types are attributable to TMB [15], indicating that other factors may influence response to these agents [8].”
BackgroundNewell, F., Pires da Silva, I., Johansson, P. A., Menzies, A. M., Wilmott, J. S., Addala, V., Carlino, M. S., Rizos, H., Nones, K., Edwards, J. J., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2021.11.012 · Cited by 164
Colorectal cancer occurrence and treatment based on changes in intestinal flora
Si, H., Yang, Q., Hu, H., Ding, C., Wang, H., & Lin, X. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.05.004 · Cited by 160
De Mattos-Arruda, L., Vazquez, M., Finotello, F., Lepore, R., Porta, E., Hundal, J., Amengual-Rigo, P., Ng, C. K. Y., Valencia, A., Carrillo, J., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.008 · Cited by 157
“26 In human cancers, a number of studies have shown that response to immune-mediated therapies, such as immune checkpoint inhibitors, correlated with high tumour mutation burden (TMB) 11–14, 20, 27–31 as well as with higher numbers of predicted neoantigens.”
BackgroundUpdate on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different
Lee, C.-H., Yelensky, R., Jooss, K., & Chan, T. A. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.04.005 · Cited by 162
Titin mutation associated with responsiveness to checkpoint blockades in solid tumors
Jia, Q., Wang, J., He, N., He, J., & Zhu, B. (2019) · JCI Insight · doi:10.1172/jci.insight.127901 · Cited by 158
“A significant relationship was established between TMB and ORR of patients treated with ICBs across multiple solid cancers (2).”
BackgroundWang, Q., Li, M., Yang, M., Yang, Y., Song, F., Zhang, W., Li, X., & Chen, K. (2020) · Aging · doi:10.18632/aging.102814 · Cited by 163
“An integrated analysis of 27 cancer types reported positive association between TMB and benefit of ICB treatment [12].”
BackgroundJin, M., Fang, J., Peng, J., Wang, X., Xing, P., Jia, K., Hu, J., Wang, D., Ding, Y., Wang, X., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02176-8 · Cited by 190
Ferrarotto, R., Amit, M., Nagarajan, P., Rubin, M., Yuan, Y., Bell, D., El‐Naggar, A. K., Johnson, J. M., Morrison, W. H., Rosenthal, D. I., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0585 · Cited by 168
“High TMB has been associated with response to PD-1 inhibitors in a variety of cancer types (13).”
BackgroundBioinspired and Biomimetic Delivery Platforms for Cancer Vaccines
Liu, J., Liew, S. S., Wang, J., & Pu, K. (2022) · Advanced Materials · doi:10.1002/adma.202103790 · Cited by 159
Synthetic lethality-mediated precision oncology via the tumor transcriptome
Lee, J. S., Nair, N. U., Dinstag, G., Chapman, L., Chung, Y., Wang, K., Sinha, S., Cha, H., Kim, D., Schperberg, A. V., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.030 · Cited by 158
“8 Cell 184, 1–16, April 29, 2021 observed in anti-PD1 clinical trials of 16 cancer types (Lee and Ruppin, 2019; Yarchoan et al., 2017).”
BackgroundBhat, A. A., Yousuf, P., Wani, N. A., Rizwan, A., Chauhan, S. S., Siddiqi, M. A., Bedognetti, D., El-Rifai, W. M., Frenneaux, M. P., Batra, S. K., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00419-w · Cited by 183
Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies
To, K. K. W., Fong, W., & Cho, W. C. S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.635007 · Cited by 175
“Interestingly, EGFR mutant NSCLC is more enriched in the never smoking population (63).”
BackgroundKim, J. Y., Kronbichler, A., Eisenhut, M., Hong, S. H., van der Vliet, H. J., Kang, J., Shin, J. I., & Gamerith, G. (2019) · Cancers · doi:10.3390/cancers11111798 · Cited by 165
“[24] showed that the response rate correlated with TMB.”
MethodResultYin, Z., Yu, M., Ma, T., Zhang, C., Huang, S., Karimzadeh, M. R., Momtazi‐Borojeni, A. A., & Chen, S. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001698 · Cited by 162
Metadata
- Authors
- Yarchoan, M., Hopkins, A., & Jaffee, E. M.
- Affiliations
- Johns Hopkins University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-12-21
- Volume
- 377
- Issue
- 25
- Pages
- 2500-2501
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6549688
- OpenAlex
- W2779221466
- Cited by
- 3,230
- References
- 5
- Citations by year
- 2026: 181 · 2025: 274 · 2024: 410 · 2023: 460 · 2022: 525 · 2021: 558 · 2020: 408 · 2019: 255 · 2018: 153 · 2017: 1
- FWCI
- 98.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P30CA006973)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tumor mutational burden, anti-PD-1 therapy, PD-L1 blockade, immune checkpoint inhibitors, cancer immunotherapy response, predictive biomarkers, cancer types
- MeSH terms
- Antineoplastic Agents, DNA Mutational Analysis, Humans, Models, Genetic, Mutation, Neoplasms, Biomarkers, Tumor, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.